DexCom, Inc.
NASDAQDXCM enters the back half of August with a clear split: short sellers are actively reducing exposure while options traders have quietly moved to their most defensive posture in a year — a tension worth watching as the stock consolidates a 25% monthly gain near $89. The short side of the ledger is telling a retreat story. Short interest has dropped 8.6% on the week and 15.5% over…
Snapshot as of 28 Sept 2026
DXCM enters the back half of August with a clear split: short sellers are actively reducing exposure while options traders have quietly moved to their most defensive posture in a year — a tension worth watching as the…
DXCM delivered a Q2 earnings beat that flipped the script entirely — the defensive hedging that dominated the pre-print note has given way to a broad analyst upgrade cycle and the stock's strongest weekly move in…
DXCM heads into tonight's Q2 earnings report with options traders flashing their most defensive positioning in nearly a year. The put/call ratio has climbed to 1.00, more than two standard deviations above its 20-day…
DexCom enters the week after a 29% one-month rally with an unusual split: analysts are lifting targets in its wake, yet options traders just registered their most defensive positioning of the year — a tension worth…
DexCom heads into its Q1 2026 earnings report with options markets flashing their most cautious signal in months. The put/call ratio jumped to 1.05 on the day of the print — nearly three standard deviations above its…
Options traders are pricing in more pain for DXCM. Three bearish signals converged this week — rising short interest, a spiking put-call ratio, and a higher cost to borrow — all arriving just 12 days before DexCom's…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DXCM — free to start on ORTEX.
Sign up for free →Open DXCM on ORTEX